EPHX2 and diabetic kidney disease: Previous results have shown that genetic disruption or pharmacological inhibition of sEH partially reversed albuminuria, morphological changes, and renal dysfunction in diabetic kidney disease and lupus nephritis [12,13,16,17,18,19].